Japanese clinical practice guidelines for congenital biliary dilatation

the Japanese Study Group on Congenital Biliary Dilatation (JSCBD)

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Practice Guidelines
Dilatation
Guidelines
Committee Membership
Clinical Pathology

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Japanese clinical practice guidelines for congenital biliary dilatation. / the Japanese Study Group on Congenital Biliary Dilatation (JSCBD).

In: Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 24, No. 1, 01.01.2017, p. 1-16.

Research output: Contribution to journalArticle

the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) 2017, 'Japanese clinical practice guidelines for congenital biliary dilatation', Journal of Hepato-Biliary-Pancreatic Sciences, vol. 24, no. 1, pp. 1-16. https://doi.org/10.1002/jhbp.415
the Japanese Study Group on Congenital Biliary Dilatation (JSCBD). / Japanese clinical practice guidelines for congenital biliary dilatation. In: Journal of Hepato-Biliary-Pancreatic Sciences. 2017 ; Vol. 24, No. 1. pp. 1-16.
@article{b61d5ec04ae1408cb57383f6275cb2a7,
title = "Japanese clinical practice guidelines for congenital biliary dilatation",
abstract = "Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.",
author = "{the Japanese Study Group on Congenital Biliary Dilatation (JSCBD)} and Hiroki Ishibashi and Mitsuo Shimada and Terumi Kamisawa and Hideki Fujii and Yoshinori Hamada and Masayuki Kubota and Naoto Urushihara and Itaru Endo and Masaki Nio and Tomoaki Taguchi and Hisami Ando",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/jhbp.415",
language = "English",
volume = "24",
pages = "1--16",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Japanese clinical practice guidelines for congenital biliary dilatation

AU - the Japanese Study Group on Congenital Biliary Dilatation (JSCBD)

AU - Ishibashi, Hiroki

AU - Shimada, Mitsuo

AU - Kamisawa, Terumi

AU - Fujii, Hideki

AU - Hamada, Yoshinori

AU - Kubota, Masayuki

AU - Urushihara, Naoto

AU - Endo, Itaru

AU - Nio, Masaki

AU - Taguchi, Tomoaki

AU - Ando, Hisami

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.

AB - Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.

UR - http://www.scopus.com/inward/record.url?scp=85011601826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011601826&partnerID=8YFLogxK

U2 - 10.1002/jhbp.415

DO - 10.1002/jhbp.415

M3 - Article

C2 - 28111910

AN - SCOPUS:85011601826

VL - 24

SP - 1

EP - 16

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 1

ER -